Pathology of nonalcoholic fatty liver disease

Annals of Gastroenterology

Volumn 18, Issue 2, 2005, Pages 148-159

  Tiniakos, Dina G ^a   Kittas, Ch ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Liver; Nonalcoholic; Pathology; Steatohepatitis; Steatosis

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; GLYCOGEN; IRON; LEPTIN; LIVER ENZYME; PLACEBO; RESISTIN; ROSIGLITAZONE; URSODEOXYCHOLIC ACID;

ALCOHOLIC FATTY LIVER; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; MALLORY BODY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; POPULATION RESEARCH; PREVALENCE; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; STEATOSIS;

EID: 34548526626     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
3. Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004; 8: 861-879.
4. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.
5. Ruhl CE, Everhart JE. Epidemiology of non-alcoholic fatty liver. Clin Liver Dis 2004; 8: 501-519.
6. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis- Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
7. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
8. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
9. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
10. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455.
11. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
12. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004; 36: 165-173.
13. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Liver Dis 1998; 15: 246-258.
14. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis 2001; 21:3-16.
15. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
16. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
17. Caldwell SH, Crespo DM. A commentary to "The spectrum expanded: cryprogenic cirrhosis and the natural history of non-alcoholic liver disease" by Powell EE, Cooksley WGE, Hanson R, et al: J Hepatol 2004; 40: 578-584.
18. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in non-alcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-427.
19. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of non-alcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826.
20. Adams L, Lymp J, Sauver S, et al. The natural history of non-alcoholic fatty liver disease: A population based cohort study (Abstract). Hepatology 2004; 40: 582A.
21. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169-2175.
22. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
23. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
24. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-1493.
25. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-160.
26. Mori S, Yamasaki T, Sakaida I, et al. Hepatocellular carcinoma with non-alcoholic steatohepatitis. J Gastroenterol 2004; 39: 391-396.
27. Hashimoto E, Taniai M, Kaneda H, et al. Comparison of hepatocellular carcinoma patients with alcoholic liver disease and non-alcoholic steatohepatitis. Alcohol Clin Exp Res 2004; 28(suppl. 8): 164S-168S.
28. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterolgy 2003; 123: 745-750.
29. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic Resonance Spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-468.
30. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539-943.
31. Shalhub S, Parsee A, Gallagher SF, et al. The importance of routine liver biopsy in diagnosing non-alcoholic steatohepatitis in bariatric patients. Obes Surg 2004; 14: 54-59.
32. Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 691-707.
33. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16: 49-56.
34. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in over-weight patients. Gastroenterology 2000; 118: 1117-1123.
35. Garcia-Monzon C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-724.
36. Gramlich T, Kleiner DE, Mc Cullough AJ, Matteoni C, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004; 35: 196-199.
37. Connor CL. Fatty infiltration of liver and development of cirrhosis in diabetes and chronic alcoholics. Am J Pathol 1938; 14: 347.
38. Westwater JO, Fainer D. Liver impairment in the obese. Gastroenterology 1958; 34: 686-693.
39. Thaler H. The fatty liver and its pathogenetic relation to liver cirrhosis. German. Virchows Arch Pathol Anat Physiol Klin Med 1962; 335: 180-210.
40. Peters RL, Gay T, Reynolds TB. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic hepatic disease. Am J Clin Pathol 1975; 63: 318-331.
41. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67: 811-816.
42. Nasrallah SM, Wills CE, Galambos JT. Hepatic morphology in obesity. Dig Dis Sci 1981; 26: 325-327.
43. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990; 85: 1349-1355.
44. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatoliepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
45. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34: 255-262.
46. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
47. Youssef WI, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002; 13: 17-30.
48. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
49. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
50. Vuppalanchi R, Matsumoto M, Cummings OW, et al. Histological grading of hepatic steatosis by pathologists does not correlate with hepatic triglyceride content (Abstract) Hepatology 2004; 40: 985.
51. Caldwell SH, Chang C, Krugner-Higby LA, Redick JA, Davis CA, Al-Osaimi AMS. The ballooned hepatocyte in NAFLD: Degenerative or adaptive? (abstract) J Hepatol 2004; 40(suppl 1): 168.
52. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-443.
53. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of non-alcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1718-1719.
54. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001; 34: 248-253.
55. Ziol M, Tepper M, Lohez M, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol 2001; 34: 254-260.
56. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of non-alcoholic fatty liver disease. Hepatology 2004; 40: 475-483.
57. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000; 31: 822-828.
58. Cortez-Pinto H, Baptista A, Camilo ME, deMoura MC. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepato-Gastroenterol 2001; 48: 87-90.
59. Feldstein AE, Papuchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cell activation score predicts fibrosis progression in patients with nonalcoholic fatty liver disease. (Abstract) Hepatology 2004; 40: 76.
60. Denk H, Stumptner C, Zatloukal K. Mallory bodies revisited. J Hepatol 2000; 32: 689-702.
61. Muller T, Langner C, Fuchsbichler A, et al. Immunohistochemical analysis of Mallory bodies in Wilsonian and non-Wilsonian hepatic copper toxicosis. Hepatology 2004; 39: 963-969.
62. Zatloukal K, Stumptner C, Fuchsbichler A, et al. The keratin cytoskeleton in liver diseases. J Pathol 2004; 204: 367-376.
63. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-434.
64. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
65. Le TH, Caldwell SH, Redick JA, et al. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatoliepatitis. Hepatology 2004; 39: 1423-1429.
66. Caldwell SH, Chang CY, Nakamoto RK, Kruper-Higby L. Mitochondria in non-alcohohc fatty liver disease. Clin Liver Dis 2004; 8: 595-617.
67. George DK, Goldwurm. S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318.
68. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis- an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
69. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-850.
70. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased pr evalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429.
71. Chitturi S, Weltman M, Farrell GC, et al. Mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-149.
72. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations and insulin resistance to fibrosis in non-alcoholic fatty liver. Hepatology 2004; 39: 179-187.
73. Itoh S, Yougel, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82: 650-654.
74. Cortez-Pinto H, Baptista A, Camilo ME, Valente A, Saragoca A, DeMoura MC: Nonalcoholic steatohepatitis - clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41: 172-179.
75. Abrams GA, Jhala N, Lazenby AJ, et al. Comparison of paired liver biopsies in morbidly obese subjects with non-alcoholic fatty liver disease. Gastroenterology 2004; 126: A755.
76. Ratziu V, Charlotte F, Heurtier A, et al. High sampling variability of percutaneous liver biopsy in non-alcoholic fatty liver disease. Hepatology 2004; 40: 237A.
77. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 2004; 39: 188-196.
78. Newschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improvement in nonoalcholic steato-hepatitis following 48 weeks of treatment with the PPAR-g ligand rosiglitazone. Hepatology 2003; 38: 1008-1017.
79. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-778.
80. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and Vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490.
81. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.
82. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39: 1647-1654.
83. Nagore N, Scheuer PJ. The pathology of diabetic hepatitis. J Pathol 1988; 156: 155-160.
84. Stone BG, Van Thiel DH. Diabetes mellitus and the liver. Semin Liver Dis 1985; 5: 8-28.
85. Falchuk KR, Conlin D. The intestinal and liver complications of diabetes mellitus. Adv Intern Med 1993; 38: 269-286.
86. Latry P, Bioulac-Sage P, Echinard E, et al. Perisinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients. Hum Pathol 1987; 18: 775-780.
87. Marubbio AT, Buchwald H, Schwartz MZ, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity and after jejunoileal. bypass. Am J Clin Pathol 1976; 66: 684-691.
88. Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury followingjejunoileal bypass for morbid obesity. Liver 1987; 7: 271-276.
89. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110.
90. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229.
91. Dixon JB, Bhatal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
92. Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21: 59-67.
93. Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non-alcoholic steatohepatitis in children and adolescents. Med J Austr 2000; 173: 476-479.
94. Roberts EA. Nonalcoholic steatohepatitis in children. Curr Gastroenterol Rep 2003; 5: 253-259.
95. Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric non-alcoholic fatty liver disease. J Pediatr 2003; 143: 500-505.
96. Lavine JE, Schwimmer JB. Nonalcoholic fatty liver disease in the pediatric population. Clin liver Dis 2004; 8: 549-558.
97. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. New Engl J Med 2004; 350: 2362-237.
98. Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch Dis Child 2004; 89: 648-652.
99. Schwimmer JB, Behling C, Newbury R, et al. The histological features of pediatric fatty liver disease. Hepatology 2002; 36(suppl 1): 412A.
100. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995; 22: 1714-1719.
101. Dam-Larsen S, Franzman M, Andersen IB, et al. Long-term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755.
102. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995; 20: 127-130.
103. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004; 4: 686-693.
104. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steels JL, Wiesner RH. Recurrence of non-alcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 1802-1805.
105. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373.
106. Kleiner DE, Brunt EM, Van Natta ML, et al. Design and validation of a histologic scoring system for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato-hepatitis. Hepatology 2003; 38(suppl 1): 160.
107. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002; 6: 399-420.
108. French SW, Nash J, Shitabata P, et al. Pathology of alcoholic liver disease. Semin Liv Dis 1993; 13: 154-169.
109. Baptista A, Bianchi L, de Groote J, et al. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981; 1: 707-711.
110. Burt AD, MacSween RNM. Hepatic vein lesions in alcoholic liver disease: retrospective biopsy and necropsy study. J Clin Pathol 1986; 39: 63-67.
111. MacSween RNM, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liv Dis 1986; 6:221-232.
112. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
113. Laine F, Bendavid C, Moirand R, et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology 2004; 39: 1639-1646.
114. Czaja MJ. Liver injury in the setting of steatosis: cross-talk between adipokine and cytokine: Hepatology 2004; 40: 19-22.
115. Hui JM, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
116. Gawrieh S, Rosado B, Lindor K, Charlton MR. Adipokine levels are predictive-of histology in patients with non-alcoholic fatty liver disease. Hepatology 2004; 40: 237A.
117. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 2002; 24: 429-438.
118. Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 2002; 16: 767-781.
119. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567-571.
120. Brunt EM, Tiniakos DG. Steatosis, steatohepatitis: review of effects on chronic hepatitis C. Curr Hepatitis Rep 2002; 1: 38-44.
121. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004; 40: 533-535.
122. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001; 21: 266-271.
123. Younossi ZM, McCullough, AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004; 38: 705-709.
124. Hu KQ, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of hepatitis C: a retrospective study on a large cohort of patients in the United states. J Hepatol 2004; 40: 147-154.